{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:49:43Z","timestamp":1791409783228,"version":"4.3.3"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.annonc.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:59:35Z","timestamp":1789495175000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is it time to reassess standard toxicity and patient-reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0665-5210","authenticated-orcid":false,"given":"E.","family":"Nally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2275-6067","authenticated-orcid":false,"given":"J.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-6109","authenticated-orcid":false,"given":"M.M.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"B.I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-9924","authenticated-orcid":false,"given":"M.B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.B.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-5095","authenticated-orcid":false,"given":"D.F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2026.09.003_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.003_bib2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.003_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.annonc.2026.09.003_bib4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.annonc.2026.09.003_bib5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.003_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.annonc.2026.09.003_bib7","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.19.00345","article-title":"Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition\u2013a pooled analysis of patients with advanced melanoma","volume":"37","author":"Regan","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.003_bib8","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.003_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.003_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002535","article-title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis","volume":"9","author":"Tarhini","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.003_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.003_bib12","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.euo.2025.07.012","article-title":"Development of a health-related quality of life questionnaire for patients with metastatic or localized renal cell carcinoma","volume":"8","author":"Bergerot","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.003_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/oncolo\/oyad231","article-title":"Patient-reported outcomes in KEYNOTE-564: adjuvant pembrolizumab versus placebo for renal cell carcinoma","volume":"29","author":"Choueiri","year":"2024","journal-title":"Oncologist"},{"issue":"suppl 7","key":"10.1016\/j.annonc.2026.09.003_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2026.44.7_suppl.420","article-title":"Patient-reported outcomes in resected renal cell carcinoma: active monitoring vs. durvalumab and tremelimumab in the RAMPART trial","volume":"44","author":"Merrick","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.003_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.24.00773","article-title":"Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: part B of the randomized, placebo-controlled, phase III CheckMate 914 Trial","volume":"43","author":"Motzer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.003_bib16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.annonc.2025.10.011","article-title":"Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial","volume":"37","author":"Powles","year":"2026","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.003_bib17","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1200\/JCO.2026.44.16_suppl.4512","article-title":"Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma","volume":"44","author":"Nally","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:57:19Z","timestamp":1791406639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426066354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"alternative-id":["S0923753426066354"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.003","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is it time to reassess standard toxicity and patient-reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)?","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}